Get started
SD BIOSENSORSS

SD BIOSENSOR

9,060KRWD
−210−2.27%
At close at 09:08 GMT
KRW
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

137310 fundamentals

Key facts

Market capitalization‪1.12 T‬KRW
Dividend yield (indicated)2.16%
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−805.31KRW
Founded2010
Employees (FY)—
CEOHyo-Geun Lee
Websitesdbiosensor.com
About

SD Biosensor, Inc. develops and manufactures cholesterol, blood glucose testing and monitoring equipment. Its products include Standard Q, Standard F, Standard E, Standard M and BGMS. The company is founded on December 21, 2010 and is headquartered in Suwon-si, South Korea.

Ownership
‪‪117.81 M‬‬
Closely held shares
‪‪85.64 M‬‬ (72.7%)
Free Float shares
‪‪32.17 M‬‬ (27.3%)
Closely held shares
‪‪85.64 M‬‬ (72.7%)
Free Float shares
‪‪32.17 M‬‬ (27.3%)
Capital structure
Market cap
‪‪1.12 T‬‬
Debt
‪‪606.52 B‬‬
Minority interest
‪‪8.95 B‬‬
Cash & equivalents
‪‪466.13 B‬‬
Enterprise value
‪‪1.27 T‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.12 T‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
1.63x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
1.63x
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪0.60‬
‪1.20‬
‪1.80‬
‪2.40‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−80%‬
‪−40%‬
‪0%‬
‪40%‬
‪80%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−200.00 B‬‬
‪‪−100.00 B‬‬
‪0.00‬
‪‪100.00 B‬‬
‪‪200.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−200.00 B‬‬
‪‪−100.00 B‬‬
‪0.00‬
‪‪100.00 B‬‬
‪‪200.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−200.00 B‬‬
‪‪−100.00 B‬‬
‪0.00‬
‪‪100.00 B‬‬
‪‪200.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Other Products
Immunochemical Diagnosis
Other (Goods, Services, Etc.)
Self-monitoring of Blood Sugar Level
Molecular Diagnostics
By country
Period: 2024
America
Europe
Asia
South Korea
India
Africa

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪55.00 B‬‬
‪‪110.00 B‬‬
‪‪165.00 B‬‬
‪‪220.00 B‬‬
Actual
Estimate
Earnings
Next:Mar 26, 2026
2021
2022
2023
2025
‪‪−8.00 K‬‬
‪0.00‬
‪‪8.00 K‬‬
‪‪16.00 K‬‬
‪‪24.00 K‬‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
−24.84%
Payout ratio (TTM)
Dividend yield TTM
2.16%
Last payment
200.00
Last ex-date
Dec 27, 2024
Dividend history
‪0.0%‬
‪0.9%‬
‪1.8%‬
‪2.7%‬
‪3.6%‬
2020
2021
2022
2023
2024
‪0.00‬
‪350.00‬
‪700.00‬
‪‪1.05 K‬‬
‪‪1.40 K‬‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−210.00 B‬‬
‪0.00‬
‪‪210.00 B‬‬
‪‪420.00 B‬‬
‪‪630.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪800.00 B‬‬
‪‪1.60 T‬‬
‪‪2.40 T‬‬
‪‪3.20 T‬‬
Assets
Liabilities